IDENTIFY Study Results Published in PLOS ONE WASHINGTON–(BUSINESS WIRE)–CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces the publishing of the IDENTIFY Study in PLOS ONE, the multicenter validation of a machine learned (ML) phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end […]
Coronary/Structural Heart
Cardio Diagnostics Named to Fast Company’s Second Annual List of the Next Big Things in Tech
List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, today announced that it has been named to Fast Company’s second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from agriculture and environment […]
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
Platform simplifies life support, making life-saving technology more accessible to hospitals and critically ill patients LONDON–(BUSINESS WIRE)–LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S. Food and Drug Administration (FDA) for LifeSPARC™, the Company’s […]
Verve Medical Announces Results of Feasibility Trial for Transurethral Renal Pelvic Denervation for Uncontrolled Hypertension
Study of the Verve RPD™ Renal Pelvic Denervation System Shows 20.3 mm Hg Reduction in Blood Pressure in Patients with Uncontrolled Hypertension PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (“Verve”) today announced the detailed results from a feasibility trial evaluating a novel ablation therapy that achieved therapeutically significant blood pressure (“BP”) reduction for […]
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid elimination of persistent congestion following intensive DSR therapy Considerable benefit in cardio-renal status maintained till end of study (16 weeks post-intensive DSR therapy) Dramatic and sustained improvement in diuretic response up to 15 months post […]
MemorialCare Medical Group Nationally Recognized by the American Heart Association and American Medical Association for Type 2 Diabetes and Blood Pressure Cases
LONG BEACH, Calif., Nov. 14, 2022 /PRNewswire/ — MemorialCare Medical Group has received the American Heart Association’s Get With The Guidelines® – Target: Type 2 DiabetesSM Gold Certificate of Recognition, as well as the American Heart Association/American Medical Association’s Get With The Guidelines® – Target BPTM Gold Plus Quality Achievement Award. The awards celebrate MemorialCare Medical Group’s commitment […]
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
— VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides — — Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 — DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) — […]
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
PRINCETON, N.J., Nov. 14, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial, achieving the […]
Announcing Olink® Flex, a new, unique and fully flexible low-plex proteomics solution using absolute quantification
UPPSALA, Sweden, Nov. 14, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Flex, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel. With the introduction of Olink® Flex, the […]
Hello Heart Adds Breakthrough Artificial Intelligence (AI) Capabilities to Empower Users to Make Better Choices
Users now have access to deeper insights and personalization to support positive choices regarding their heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced Dot-to-Dot, a new addition to their digital whole heart health program. Dot-to-Dot is a breakthrough feature that […]



